Table 1.
Clinical Data of the Patients
| TKIs-Resistant | TKIs-Intolerant | P value | ||
|---|---|---|---|---|
| Number | 42 | 21 | ||
| Gender | (Male/Female) | 26/16 | 11/10 | Χ2=0.524 P=0.589a |
| Age | 38.5 (19, 66) | 49.0 (31, 65) | P=0.068b | |
| Disease staging | Χ2=0.554 P=0.768a | |||
| CP | 29 | 16 | ||
| AP/BC | 13 | 5 | ||
| Clinical data at diagnosis | WBC (×109/L) | 201 (32.95, 406.54) | 232.03 (37.02, 508) | P=0.212b |
| HGB(g/L) | 100.1(66, 140) | 82.36(225, 1790) | F=6.426 P=0.017c | |
| PLT (×109/L) | 572.84(49, 1197) | 732.18(225, 1790) | F=1.272 P=0.269c | |
| BM blast (%) | 1.0(0, 17.0) | 3.0(0.5, 7.5) | P=0.085b | |
| Spleen size (subcostal length/cm) | 4.8(0, 23) | 4(0, 23) | P=0.506b | |
| Sokal | 0.98(0.22,1.56) | 0.98(0.11,2.32) | P=0.484b | |
| Low | 16(38.1%) | 5(23.8%) | ||
| Medium | 16(38.1%) | 12(57.1%) | ||
| High | 10(23.8%) | 4(19%) | ||
| EUTOS | 66.5(7, 112) | 56.4(11.4, 101) | P=0.743b | |
| Low | 25(59.5%) | 16(76.2%) | ||
| High | 15(35.7%) | 5(23.8% | ||
| Clinical data at detection | WBC (×109/L) | 5.54(1.93;149.87) | 4.6(1.48;11.8) | P=0.035 b |
| HGB(g/L) | 111(49;165) | 108.5(43;131) | P=0.236 b | |
| PLT (×109/L) | 156(12;1126) | 34(6;75) | P=0.000 b | |
| EOS (%) | 0.4(0;9.7) | 0.35(0;2.9) | P=0.704 b | |
| BASO (%) | 1.2(0;18) | 0.75(0;8.9) | P=0.470 b | |
| Additional chromosomal aberrations* | P=1.000d | |||
| Yes | Major route | 4(12.12%) | 3(20%) | |
| Minor route | 4(12.12%) | 1(6.67%) | ||
| No | 25(75.76%) | 11(73.33%) | ||
| Achieved MMR | ||||
| Yes | 1(2.94%) | 1(5.00%) | ||
| No | 33(97.06%) | 19(95.00%) | ||
Notes: aChi-square test. bWilcoxon rank sum test. ct-test. dFisher’s exact test. *Only 48 patients with karyotype analysis.
Abbreviations: TKIs, tyrosine kinase inhibitors; WBC, white blood cell; HGB, hemoglobin; PLT, platelets; BM, bone marrow; EOS, eosinophil; BASO, basophil; MMR, major molecular remission.